Fig. 4

JC-001 enhances the chemosensitivity of the LLC1 tumor model to CDDP. a Tumor mass. b Percentages of tumor/non-tumor-bearing mice in the groups (n = 16). *p < 0.05, **p < 0.01 compared with the control group, #p < 0.05 compared with the CDDP-treated group. After JC-001/CDDP combined therapy, the percentage of non-tumor-bearing mice was significantly enhanced from 6.25% to 50% compared with the control group, p = 0.0031